Patents by Inventor Thierry Velu

Thierry Velu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dendritic-like cell/tumor cell hybrids and hybridomas for inducing an anti-tumor response
    Publication number: 20090081127
    Abstract: The present invention relates to a method of producing a plurality of dendritic cell/tumor cell hybrids which induce an anti-tumor response when applied to a patient. The present invention further relates to a method of producing a dendritic cell/tumor cell hybridoma which induces an anti-tumor response when applied to a patient.
    Type: Application
    Filed: May 27, 2008
    Publication date: March 26, 2009
    Inventors: Muriel Moser, Leo Oberdan, Laurence Lespagnard, Jacques Urbain, Catherine Bruyns, Catherine Gerard, Michel Goldman, Thierry Velu, Fabienne Willems, Nicole Tasiaux, Jason Perret, Anne-Marie Verheyden, Pascal Mettens, Kris Thielemans
  • Antibiotic inducible/repressible genetic construct for gene therapy or gene immunization
    Patent number: 6780639
    Abstract: The present invention is related to an antibiotic inducible/repressible genetic construct for controlling the transcription of a gene of interes: by a cell. The genetic construct comprises a bi-directional antibiotic controlled activator-responsive promoter/operator sequence which is located between the gene of interest and a cistron encoding a reverse antibiotic controlled transactivator and controls the transcription of the gene of interest and of the cistron.
    Type: Grant
    Filed: August 24, 2000
    Date of Patent: August 24, 2004
    Assignee: Universite Libre de Bruxelles
    Inventors: Abdelwahed Chtarto, Liliane Tenenbaum, Marc Levivier, Marc Peschanski, Jacques Brotchi, Thierry Velu
  • Dendritic-like cell/tumor cell hybrids and hybridomas for inducing an anti-tumor response
    Publication number: 20030118562
    Abstract: The present invention is related to hybrids and hybridomas consisting of a fused tumor cell and a dendritic cell, which is capable of inducing an anti-tumor response in vivo when administered to a subject in need of anti-tumor treatment. A method of activating autologous immune cells in vitro is disclosed, wherein the method comprises co-cultivating a dendritic cell/tumor cell hybridoma or a plurality of dendritic cell/tumor cell hybrids with immune cells from a mammalian subject.
    Type: Application
    Filed: January 24, 2002
    Publication date: June 26, 2003
    Inventors: Muriel Moser, Leo Oberdan, Laurence Lespagnard, Jacques Urbain, Catherine Bruyns, Catherine Gerard, Michel Goldman, Thierry Velu, Fabienne Willems, Nicole Tasiaux, Jason Perret, Anne-Marie Verheyden, Pascal Mettens, Kris Thielemans
  • Dendritic-like cell/tumor cell hybrids and hybridomas for inducing an anti-tumor response
    Publication number: 20030031656
    Abstract: The present invention relates to a method of producing a plurality of dendritic cell/tumor cell hybrids which induce an anti-tumor response when applied to a patient. The present invention further relates to a method of producing a dendritic cell/tumor cell hybridoma which induces an anti-tumor response when applied to a patient.
    Type: Application
    Filed: February 7, 2002
    Publication date: February 13, 2003
    Inventors: Muriel Moser, Leo Oberdan, Laurence Lespagnard, Jacques Urbain, Catherine Bruyns, Catherine Gerard, Michel Goldman, Thierry Velu, Fabienne Willems, Nicole Tasiaux, Jason Perret, Anne-Marie Verheyden, Pascal Mettens, Kris Thielemans
  • Dendritic-like cell/tumor cell hybrids and hybridomas for inducing an anti-tumor response
    Publication number: 20020141973
    Abstract: The present invention is related to a plurality of dendritic-like cell/tumor cell hybrids which is capable of inducing an anti-tumor response.
    Type: Application
    Filed: September 10, 2001
    Publication date: October 3, 2002
    Inventors: Muriel Moser, Leo Oberdan, Laurence Lespagnard, Jacques Urbain, Catherine Bruyns, Catherine Gerard, Michel Goldman, Thierry Velu, Fabienne Willems, Nicole Tasiaux, Jason Perret, Anne-Marie Verheyden, Pascal Mettens, Kris Thielemans
  • Dendritic-like cell/tumor cell hybrids and hybridomas for inducing an anti-tumor response
    Publication number: 20010012632
    Abstract: A method produces an anti-tumor response in a mammalian subject in need of anti-tumor treatment. Hybrids of tumor cells with dendritic cells or dendritic-like cells can be administered to the subject. The tumor cell of the hybrid corresponds to the tumor of the subject. Alternatively, autologous immune cells of the subject can be administered in which the immune cells are activated in vitro by co-cultivation with these hybrids.
    Type: Application
    Filed: March 9, 2001
    Publication date: August 9, 2001
    Inventors: Muriel Moser, Oberdan Leo, Laurence Lespagnard, Jacques Urbain, Catherine Bruyns, Catherine Gerard, Michel Goldman, Thierry Velu, Fabienne Willems, Nicole Tasiaux, Jason Perret, AnneMarie Verheyden
  • Method for treatment of essential (hemorrhagic) thrombocythemia
    Patent number: 4743445
    Abstract: A method for the treatment of essential thrombocythemia, said method comprising the administration of alpha-type interferons in an amount and for a period of time sufficient to reduce the platelet count to physiologically acceptable levels.
    Type: Grant
    Filed: July 25, 1985
    Date of Patent: May 10, 1988
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Francis Delwiche, Jocelyn Flament-Grivegnee, Diamond Gangji, Rita Monsieur, Pierre Stryckmans, Thierry Velu, Joseph Wybran